CAG
A short collagen-derived research peptide studied for cartilage and connective-tissue modulation.
CAG refers to a short research peptide sequence, often described as collagen-derived or cartilage-targeting, that is studied for connective-tissue and joint applications. It is proposed to modulate chondrocyte behavior and extracellular matrix components in cartilage tissue. Research is at an early preclinical stage with limited published clinical data, and the precise composition can vary by vendor.
Class
Short collagen-derived / cartilage-targeting research peptide
Half-life
Unknown
Routes
Subcutaneous, Intraarticular
Category
Longevity & Bioregulators
Researched benefits
What it's studied for
Cartilage and connective-tissue support
Proposed to support cartilage and connective tissue via modulation of collagen pathways. Short collagen-derived peptides such as Pro-Hyp and Gly-Pro-Hyp have documented activity stimulating hyaluronic acid production and collagen synthesis in chondrocytes and fibroblasts, which is the rationale for CAG's proposed effects. Evidence for CAG specifically remains preclinical.
Chondrocyte activity modulation
Studied for its proposed ability to modulate chondrocyte behavior and extracellular matrix components in joint-tissue research models. This mechanism is inferred from the activity of related collagen-derived peptide fragments rather than direct clinical data on CAG.
Potential adjunct in joint-repair stacks
Positioned in community protocols as a possible complement to established healing peptides like BPC-157 and TB-500 within joint-repair stacking approaches. This is a proposed use, not a validated clinical indication.
Mechanism
How it works
CAG is proposed to act on cartilage tissue by modulating chondrocyte behavior and the composition of the extracellular matrix. The working hypothesis draws on the known biology of short collagen-derived peptides such as Pro-Hyp and Gly-Pro-Hyp, which have documented activity stimulating hyaluronic acid production and collagen synthesis in chondrocytes and fibroblasts.
Because CAG is a vendor-defined designation rather than a single standardized molecule, its precise mechanism depends on the specific sequence supplied. It is frequently grouped and compared with other joint and connective-tissue peptides such as BPC-157, TB-500, and the Khavinson bioregulator Cartalax, which share proposed roles in tissue repair.
No detailed pharmacokinetic or receptor-level data are available for CAG. Its half-life is unknown, and the mechanistic claims above are extrapolated from related collagen peptide fragments rather than established from direct studies of CAG itself.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Research (reported)
- Dose
- Not established
- Frequency
- Once daily
- Timing
- Not specified
- Duration
- Not specified
- Route
- Subcutaneous or intraarticular
Sources list a once-daily frequency but no validated dose range; commonly supplied in 5 mg and 10 mg vials. No tiered beginner/intermediate/advanced protocol is published.
- No validated dose range exists for CAG; published sources list only a once-daily frequency and common vial sizes (5 mg, 10 mg).
- CAG is strictly preclinical with no clinical safety data — any use is experimental and should be approached with caution.
- The specific sequence and potency can vary by vendor, so reconstitution and dosing cannot be standardized from available data.
Combinations
Stacking & blends
Joint-repair stack
Connective tissue and joint repair support
CAG is proposed to complement the healing and tissue-repair activity of BPC-157 and TB-500 in joint-repair protocols, adding a collagen/cartilage pathway component.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- No clinical safety data — strictly preclinical use
There is no documented human safety profile for CAG. Interaction and contraindication data have not been compiled. Consult a qualified healthcare professional before combining research compounds.
FAQ
CAG — common questions
What is CAG used for in research?
CAG is a short research peptide, often described as collagen-derived or cartilage-targeting, studied for connective-tissue and joint applications. It is proposed to modulate cartilage and collagen tissue. Research is in early preclinical stages with limited published clinical data, and it is often compared to BPC-157, TB-500, and the Khavinson bioregulator Cartalax.
How is CAG administered?
Available data list subcutaneous and intraarticular routes, with a once-daily frequency. No validated dose range is published.
Is CAG safe?
There is no clinical safety data for CAG. It is strictly preclinical, and adverse event information is limited. It should be treated as experimental.
What forms does CAG come in?
CAG is typically supplied in vial form, commonly in 5 mg and 10 mg sizes.
How does CAG differ between vendors?
CAG is a vendor-defined designation rather than a single standardized molecule, so the exact sequence and proposed activity can depend on the specific product supplied.
